bioRxiv · 10.1101/2022.05.05.490805
ACE2 nanoparticles prevent cell entry of SARS-CoV-2
Abstract
The continual evolution of SARS-CoV-2 has challenged the efficacy of many COVID19 vaccines and treatment options. One strategy that evades viral escape is using the entry receptor, human Angiotensin-Converting Enzyme 2 (hACE2). Soluble hACE2 receptor domains show potential as decoys but genetic modifications are necessary to provide sufficient efficacy. However, these engineered constructs are potentially susceptible to viral escape. We combined native hACE2 with viral vectors to form nanoparticles presenting hACE2 analogous to human cells. Cell-based viral infection assays and cryogenic in-situ tomography show that hACE2 nanoparticles sequester viruses through aggregation, efficiently blocking entry of SARS-CoV-2 and its variants in model cell systems and human respiratory tract explants using native hACE2. Thus, we show that hACE2 nanoparticles have high potential as pan-variant COVID19 therapeutics.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Sauvanet, C., Lemos, M., Bezault, A., Rodriguez de Francisco, B., Chan, M. C., Hui, K. P., Ng, K.-c., Nicholls, J. M., Volkmann, N., Hanein, D.. 2022-05-06. ACE2 nanoparticles prevent cell entry of SARS-CoV-2. https://doi.org/10.1101/2022.05.05.490805
Cite the original work for its findings. Save a collection to share your selection of sources.